Ignite Creation Date:
2024-05-06 @ 7:54 AM
Last Modification Date:
2024-10-26 @ 11:53 AM
Study NCT ID:
NCT02627521
Status:
UNKNOWN
Last Update Posted:
2017-02-16
First Post:
2015-12-03
Brief Title:
Optimizing Timing of CABG in Patients Presenting With ACS and Treated With Ticagrelor
Sponsor:
Unity Health Toronto
Organization:
Unity Health Toronto
Study Overview
Official Title:
Optimizing Timing of Coronary Artery Bypass Surgery in Patients Presenting With Acute Coronary Syndrome and Treated With Second Generation ADP Receptor Antagonist
Status:
UNKNOWN
Status Verified Date:
2017-02
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CABG-TIME
Brief Summary:
The administration of Ticagrelor have demonstrated superiority to Clopidogrel in patients presenting with acute coronary syndrome ACS and remains a first line therapy as an adjunct to aspirin for patients admitted with ACS The patient population treated with Ticagrelor at an early time point includes non ST elevation myocardial NSTEMI patients and those undergoing primary angioplasty for ST elevation myocardial infarction STEMI It is estimated that 10-15 of patients presenting with ACS have advanced coronary artery disease requiring Coronary Artery Bypass Surgery CABG The treatment guidelines recommend a delay of 5-7 days for CABG surgery in these patients for normalization of Ticagrelor induced platelet inhibition to reduce the risk of peri-operative bleeding This delay may expose these high risk patients to adverse cardiac events while waiting for Ticagrelor effect to wean off Furthermore this empirical application of 5-7 day delay in all patients may be unnecessary due to the significant inter individual variability in response to Ticagrelor There is limited data to determine the optimum timing of CABG surgery in ACS patients treated with Ticagrelor The present study will determine the optimum timing of CABG in ACS patients treated with a loading andor maintenance dose of Ticagrelor
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None